Leopold Balleisen

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Medicine, Immunology, Oncology +7

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men.

J. J. Heinrich, Leopold Balleisen, H. Schulte et al. · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · 1994 · 566 citations · Full text

Medicine, Cardiology, Hematology +10

Epidemiological Study on Factor VII, Factor VIII and Fibrinogen in an Industrial Population: I. Baseline Data on the Relation to Age, Gender, Body-Weight, Smoking, Alcohol, Pill-Using, and Menopause

Leopold Balleisen, Jessica N. Cooke Bailey, H. Schulte et al. · Thrombosis and Haemostasis · 1985 · 348 citations

Veterinary Medicine, Endocrinology, Clinical Epidemiology +14

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

Rüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz et al. · Journal of Clinical Oncology · 2011 · 323 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +12